Cargando…
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma
Immunotherapy has revolutionized treatment for many hard-to-treat cancers but has yet to produce significant improvement in outcomes for patients with glioblastoma. This reflects the multiple and unique mechanisms of immune evasion and escape in this highly heterogeneous tumor. Glioblastoma engender...
Autores principales: | Singh, Kirit, Batich, Kristen A., Wen, Patrick Y., Tan, Aaron C., Bagley, Stephen J., Lim, Michael, Platten, Michael, Colman, Howard, Ashley, David M., Chang, Susan M., Rahman, Rifaquat, Galanis, Evanthia, Mansouri, Alireza, Puduvalli, Vinay K., Reardon, David A., Sahebjam, Solmaz, Sampson, John H., Simes, John, Berry, Donald A., Zadeh, Gelareh, Cloughesy, Tim F., Mehta, Minesh P., Piantadosi, Steven, Weller, Michael, Heimberger, Amy B., Khasraw, Mustafa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306329/ https://www.ncbi.nlm.nih.gov/pubmed/34561270 http://dx.doi.org/10.1158/1078-0432.CCR-21-2681 |
Ejemplares similares
-
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
por: Tan, Aaron C, et al.
Publicado: (2021) -
Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
por: Omuro, Antonio, et al.
Publicado: (2022) -
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience
por: Lee, Eudocia Q, et al.
Publicado: (2021) -
CLRM-07 RANO 2.0: PROPOSAL FOR AN UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
por: Wen, Patrick, et al.
Publicado: (2023) -
PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
por: Sim, Hao-Wen, et al.
Publicado: (2022)